Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Kerala Ayurveda's losses widened even as revenue grew

Standalone net loss hit ₹14.74 cr on 17.6% revenue growth; consolidated loss was ₹20.65 cr. The auditor flagged unprovided receivables from subsidiaries.

3 earlier stories on Kerala Ayurveda Ltd.
Mkt cap₹243 cr
ROE0.00%
Debt / eq.6.95
₹14.74 cr Wider standalone net loss despite higher revenue

What's new

  • Standalone net loss widened to ₹14.74 cr on revenue of ₹85.48 cr.
  • Consolidated revenue grew 9% to ₹131.15 cr but net loss was ₹20.65 cr.
  • Auditor flagged significant receivables from subsidiaries with no provision.

Why this matters

Revenue growth that doesn't translate to profit is a familiar problem, but the auditor's emphasis on unprovided subsidiary receivables adds a governance question to the usual operational one. The company is growing the top line but not converting it into earnings.

What we're watching

  • How management addresses the auditor's receivable concern.
  • Whether the subsidiary receivables get provisioned in coming quarters.
  • Path to profitability after another year of widening losses.

The full read

Kerala Ayurveda grew standalone revenue 17.6% to ₹85.48 crore in FY26, but the ₹14.74 crore net loss was wider than the prior year. The consolidated picture is similar: 9% revenue growth to ₹131.15 crore with a net loss of ₹20.65 crore. The auditor's report adds a wrinkle, flagging significant receivables from subsidiaries with no provision set aside. That is the number to watch. Growing revenue while losing more money is one thing; doing it while your own subsidiaries owe you unprovided balances is another. The filing is a routine annual disclosure, but the auditor's emphasis gives the market a specific governance question to digest.

Questions answered

How did Kerala Ayurveda's profitability change?
Standalone net loss widened to ₹14.74 crore, even as revenue grew 17.6% to ₹85.48 crore. The consolidated net loss was ₹20.65 crore on ₹131.15 crore revenue.
What did the auditor flag?
The audit report includes an emphasis of matter on significant outstanding trade receivables from subsidiaries that have not been provisioned for.
Why are unprovided subsidiary receivables a concern?
They represent money owed to the parent by its own subsidiaries, and without a provision, the company's asset book may be overstated relative to its ability to collect.
Is this a routine filing?
Yes, it is a standard quarterly and annual financial result announcement required by SEBI LODR rules. The underlying numbers were already widely disseminated.
Mentioned: Kerala Ayurveda Ltd. · ₹14.74 cr standalone loss · ₹20.65 cr consolidated loss
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Kerala Ayurveda Ltd.

Pharmaceuticals
₹275 cr

Latest quarter · Dec 2025

Sales₹33 cr
Net profit−₹5 cr
Op. margin−4.6%
EPS−₹3.69

Strength & growth

Debt / equity6.95×
Current ratio0.46×
Sales CAGR+15.1%
  1. 25 May 2026 · 8:07 PM IST Kerala Ayurveda's losses widened even as revenue grew
  2. 53d ago Kerala Ayurveda targets ₹200 cr revenue by FY27
  3. 53d ago Kerala Ayurveda's losses widen even as revenue climbs
  4. 53d ago Kerala Ayurveda's losses widen even as top line grows